Search for: "Cephalon, Inc."
Results 1 - 20 of 59
Sorted by Relevance | Sort by Date
14 Feb, 2008 6:39 am
Cephalon issued a press release yesterday, February 13, 2008, that reads, in part: Cephalon, Inc., (Nasdaq: CEPH) issued the following statement in response to a
complaint filed today by the U.S. Federal Trade Commission (FTC) ... modafinil) [C-IV] patent infringement litigation and seeking to permanently enjoin the Company from maintaining or
enforcing these agreements. Cephalon stands by the strength and validity of our PROVIGIL patents and the legal basis for these settlements. We are disappointed ...
14 Feb, 2008 6:39 am
Cephalon issued a press release yesterday, February 13, 2008, that reads, in part: Cephalon, Inc., (Nasdaq: CEPH) issued the following statement in response to a
complaint filed today by the U.S. Federal Trade Commission (FTC) ... modafinil) [C-IV] patent infringement litigation and seeking to permanently enjoin the Company from maintaining or
enforcing these agreements. Cephalon stands by the strength and validity of our PROVIGIL patents and the legal basis for these settlements. We are disappointed ...
2 Apr, 2007 7:08 pm
By Mark Chael --- On March 30, 2007, Cephalon, Inc. announced that it had received an approvable letter from the U.S. Food and Drug Administration (FDA) regarding
Cephalon's Nuvigil® (armodafinil) new drug application (NDA). The approvable letter was accompanied by draft labeling that includes a proposed warning section in bold...
14 Feb, 2008 7:09 am
... had challenged the only remaining patent covering Provigil, one relating to the size of particles used in the product. The complaint charges that Cephalon was able to induce
each of the generic companies to abandon its patent challenge and agree to refrain from selling a ... years earlier, on the first day permitted by regulation, four companies - Teva
Pharmaceuticals USA, Inc. (Teva), Ranbaxy Pharmaceuticals, Inc. (Ranbaxy), Mylan Pharmaceuticals Inc. (Mylan), and Barr Laboratories, Inc. (Barr) - ...
19 Oct 4:30 am
... regulatory approval. Central Regional Employees Benefit Fund, et al. v. Cephalon Inc., No. 09-cv-03418 (D.N.J. Oct. 15, ... Complaint fails to identify or explain the
who,what, where, why, and how of any "transaction." Mere allegations that Cephalon provided prescription drugs, without saying to whom or under what circumstances, wholly failed
... Claims Act, 31 U.S.C. § 3729 et seq., wherein Cephalon was alleged to have engaged in "misbranding" of its products. However, referring to a plea agreement and ...
13 Sep, 2007 6:08 pm
... than the recommended dosage. The other person that died committed suicide. None of the victims were being treated for cancer. Cephalon says that the deaths are not connected
to allegations (still under investigation) that the manufacturer improperly promoted FENTORA and other drugs ... file a personal injury or wrongful death lawsuit. Listed on the FENTORA
Web site are key points provided by Cephalon, Inc. regarding use of the drug: • Do NOT use FENTORA in opioid non-tolerant patients • Use FENTORA ...
1 Oct, 2008 8:24 pm
Cephalon Inc., a Frazer, PA-based pharmaceutical company plead guilty in federal court for marketing 3 drugs for uses other than they were approved for. According to an
article in the Philadelphia Daily News, ... more than boosting its bottom line." Actiq, dispensed as a lollipop, is only approved for cancer patients and is a highly addictive narcotic.
Cephalon marketed it for maladies including migraines and injuries. Gabrivil is an anti-epilepsy drug used to treat seizures, but was promoted as a ...
31 Dec, 2008 11:24 am
... of Florida will receive $8.5 million of $375 million from a qui tam lawsuit and settlement between Medicaid and Cephalon, Inc. The international biopharmaceutical
company was accused of improperly marketing three prescription drugs: Provigil, Gabitril and Actiq. As a result, Cephalon has entered into a Corporate Integrity Agreement,
requiring strict scrutiny of future marketing practices. Click here to read more about Florida's ...
1 Aug, 2006 8:38 am
... surprised there is only one story about modafinil (according to a Google News search). According to MarketWatch: Mylan Laboratories Inc. (MYL) said Monday that the Federal
Trade Commission is investigating the company's patent-litigation settlement related to the sleep-disorder drug modafinil. As reported earlier this month, Cephalon Inc.
(CEPH) entered an agreement related to patent-infringement litigation with Mylan Laboratories, granting Mylan Laboratories non-exclusive ...
20 Sep, 2007 3:04 pm
... of serious skin reactions associated with the sleep disorder drug Provigil (modafinil). This medication, made by the drug company Cephalon, Inc., is prescribed to
treat patients with excessive sleepiness (ES) associated with narcolepsy, obstructive sleep apnea / ... and serious cutaneous skin reactions. As a result of these adverse event reports
associated with the use of Provigil, Cephalon has changed the package insert, or label, for Provigil to include a bolded warning for serious skin rashes, ...
25 Aug 12:37 pm
In Cephalon, Inc. v. Johns Hopkins University, No. 3505-VCP (Del. Ch. Aug. 18, 2009) read opinion here, while ruling on two motions to compel, Vice Chancellor Parsons
addressed a couple ... Disclosure of Underlying Facts Another challenging area for practitioners is the decision as to what factual information in a privileged communication must be
disclosed. Here Cephalon argued that the privilege does not protect underlying facts from disclosure and so those facts should be disclosed. ...
10 Oct, 2007 9:15 pm
... misused and improperly prescribed, according to a Public Health Advisory recently issued by the U.S. Food and Drug Administration (FDA). Manufactured by Cephalon,
Inc., Fentora is most commonly prescribed to treat breakthrough pain in terminal cancer patients who have already developed a tolerance to opioid pain medications. According to
the FDA, Fentora-associated deaths have recently occurred in non-cancer patients, and in ...
9 Sep 5:36 pm
... brought a number of actions in the federal courts alleging that "reverse payments" are illegal. In one of those actions, brand name drug manufacturer Cephalon, Inc.
has recently asked the U.S. District Court for the Eastern District of Pennsylvania to find as a matter of law that Cephalon's "reverse payment" agreement to keep generics off
the market for its brand name drug Provigil until 2012 does not violate the Sherman Act. ...
9 Oct 9:11 am
... . and Teva Pharmaceutical Industries Ltd. (patent infringement) 9/16: Dorman Products Inc. v. Gates Corporation (trademark infringement) 9/16: Fair Isaac Corporation v. ...
Philips Corporation v. Samsung Electronics Company Ltd. and Samsung Electronics America Inc. (patent infringement) 9/18: Research Foundation of State University of New York, New
... . (patent infringement) 9/25: Cephalon Inc. v. Watson Pharmaceuticals Inc., Watson Laboratories, Inc. and Watson Pharma Inc. (patent infringement)
10/5: ...
15 Jan, 2008 6:35 pm
The Cephalon Speaker Series for Science and the Constitution is a partnership between Cephalon, Inc. and the National Constitution Center intended to attract local
and national experts to discuss constitutional issues pertaining to science, public policy and the law. The first program in the series, "Regulating the Practice of Medicine," is a
conversation with industry insiders about how business and ...
Listen Now:
25 Feb, 2008 2:38 pm
... column today by Jon Leibowitz of the Federal Trade Commission, which addresses a suit recently filed by the agency against Cephalon, Inc., which will test the legality
of the practice of entering into "pay for delay" settlements. Liebowitz describes the "pay for delay ... of the market until the patent expires? Clearly, insurers and the public would
say yes. According to Liebowitz, Cephalon made an additional $4 billion dollars as a direct result form entering into this "pay for delay" settlement-- ...
27 Apr, 2008 7:35 pm
The Cephalon Speaker Series for Science and the Constitution is a partnership between Cephalon, Inc. and the National Constitution Center intended to attract local
and national experts to discuss constitutional issues pertaining to science, public policy and the law. The second program in the series, "Choices and Challenges in the New Age of Life
Sciences," is a conversation with bio-ethicists and ...
Listen Now:
13 Aug, 2008 6:46 pm
... FDA is warning doctors about severe skin reactions in alcoholism patients who use Vivitrol, an injectable treatment made and marketed by Cephalon Inc. Doctors and
patients should watch for swelling, infection, and other complications where the drug is injected. ... into muscle, not fatty tissue. More than 200 reports of skin problems have been
reported among patients. A Cephalon spokeswoman said the company believes some problems stem from improper injections. If you or someone you care about was ...
2 Oct, 2008 10:18 pm
Drug maker Cephalon Inc. will pay $431 million to settle a number of whistleblower lawsuits accusing the company of promoting drugs for unapproved uses. As part of the
global Justice Department settlement the company will also plead guilty to a ... drugs. Four whistleblowers will split a combined award of more than $46 million under the settlement.
The whistleblower suits accused Cephalon of promoting three of its drugs - Actiq, Gabitril and Provigil - for uses other than what the U.S. Food & ...
17 Oct, 2008 2:35 am
... 's role in evaluating and regulating America's medical products, specifically in the area of cancer research. The Philadelphia Inquirer's John Timpane moderates. This program is
part of the Cephalon Speaker Series for Science and the Constitution, a partnership between Cephalon, Inc. and the National Constitution Center intended to attract
local and national experts to discuss constitutional issues pertaining to science, public policy and the law. ...
Listen Now:
Search on: Blawgs.FM | BlawgSearch Google Co-op | Blawg.com | Bloglines | Feedster | Google Blog Search | Technorati | Google | MSN | Yahoo!